Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Tsuji BT, Fisher J, Boadi-Yeboah R, Holden PN, Sethi S, Pettigrew MM, Murphy TF.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01995-17. doi: 10.1128/AAC.01995-17. Print 2018 Feb.

2.

Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era.

Bulman ZP, Chen L, Walsh TJ, Satlin MJ, Qian Y, Bulitta JB, Peloquin CA, Holden PN, Nation RL, Li J, Kreiswirth BN, Tsuji BT.

MBio. 2017 Jul 25;8(4). pii: e00540-17. doi: 10.1128/mBio.00540-17.

3.

Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.

Smith NM, Bulman ZP, Sieron AO, Bulitta JB, Holden PN, Nation RL, Li J, Wright GD, Tsuji BT.

J Antimicrob Chemother. 2017 Aug 1;72(8):2297-2303. doi: 10.1093/jac/dkx121.

4.

New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.

Bulman ZP, Satlin MJ, Chen L, Kreiswirth BN, Shin BS, Walsh TJ, Holden PN, Forrest A, Nation RL, Li J, Tsuji BT.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02023-16. doi: 10.1128/AAC.02023-16. Print 2017 Apr.

5.

Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.

Bulman ZP, Ly NS, Lenhard JR, Holden PN, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00096-16. doi: 10.1128/AAC.00096-16. Print 2017 Apr.

6.

In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Int J Antimicrob Agents. 2017 Jan;49(1):25-30. doi: 10.1016/j.ijantimicag.2016.07.015. Epub 2016 Sep 1.

PMID:
27931793
7.

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah SE, Thamlikitkul V, Shin BS, Rao G, Holden PN, Walsh TJ, Forrest A, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 Jan;72(1):153-165. Epub 2016 Sep 15.

8.

Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.

Rao GG, Ly NS, Bulitta JB, Soon RL, San Roman MD, Holden PN, Landersdorfer CB, Nation RL, Li J, Forrest A, Tsuji BT.

J Antimicrob Chemother. 2016 Nov;71(11):3148-3156. Epub 2016 Aug 3.

9.

Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.

Rao GG, Ly NS, Diep J, Forrest A, Bulitta JB, Holden PN, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2016 Sep;48(3):331-6. doi: 10.1016/j.ijantimicag.2016.06.006. Epub 2016 Jul 12.

10.

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach.

Garonzik SM, Lenhard JR, Forrest A, Holden PN, Bulitta JB, Tsuji BT.

PLoS One. 2016 Jun 10;11(6):e0156131. doi: 10.1371/journal.pone.0156131. eCollection 2016.

11.

Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Pettigrew MM, Tsuji BT, Gent JF, Kong Y, Holden PN, Sethi S, Murphy TF.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4151-8. doi: 10.1128/AAC.00301-16. Print 2016 Jul.

12.

Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.

Tsuji BT, Landersdorfer CB, Lenhard JR, Cheah SE, Thamlikitkul V, Rao GG, Holden PN, Forrest A, Bulitta JB, Nation RL, Li J.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3913-20. doi: 10.1128/AAC.02831-15. Print 2016 Jul.

13.

Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.

Ly NS, Bulman ZP, Bulitta JB, Baron C, Rao GG, Holden PN, Li J, Sutton MD, Tsuji BT.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2870-80. doi: 10.1128/AAC.02377-15. Print 2016 May.

14.

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):1967-73. doi: 10.1128/AAC.02635-15. Print 2016 Apr.

15.

Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.

Bulman ZP, Sutton MD, Ly NS, Bulitta JB, Holden PN, Nation RL, Li J, Tsuji BT.

Antimicrob Agents Chemother. 2015 Jul;59(7):4343-6. doi: 10.1128/AAC.04629-14. Epub 2015 Apr 27.

16.

Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.

Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A, Bergen PJ, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2015 May;70(5):1434-42. doi: 10.1093/jac/dku567. Epub 2015 Feb 23.

17.

Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype.

Lenhard JR, von Eiff C, Hong IS, Holden PN, Bear MD, Suen A, Bulman ZP, Tsuji BT.

Antimicrob Agents Chemother. 2015 Feb;59(2):1347-51. doi: 10.1128/AAC.04508-14. Epub 2014 Dec 1.

18.

New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.

Rao GG, Ly NS, Haas CE, Garonzik S, Forrest A, Bulitta JB, Kelchlin PA, Holden PN, Nation RL, Li J, Tsuji BT.

Antimicrob Agents Chemother. 2014;58(3):1381-8. doi: 10.1128/AAC.00327-13. Epub 2013 Dec 16.

19.

Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.

Tsuji BT, Bulitta JB, Brown T, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Skerlos L, Hanna D.

J Antimicrob Chemother. 2012 Sep;67(9):2182-90. doi: 10.1093/jac/dks201. Epub 2012 Jun 8.

PMID:
22685161
20.

Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.

Tsuji BT, Brown T, Parasrampuria R, Brazeau DA, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Hanna D, Bulitta JB.

Antimicrob Agents Chemother. 2012 Jul;56(7):3712-9. doi: 10.1128/AAC.05453-11. Epub 2012 Apr 23.

21.

Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Moise PA, Smyth DS, El-Fawal N, Robinson DA, Holden PN, Forrest A, Sakoulas G.

J Antimicrob Chemother. 2008 Jan;61(1):85-90. Epub 2007 Nov 27.

PMID:
18042628

Supplemental Content

Loading ...
Support Center